A Sanofi strategy shift is leading to the end of a gene-editing alliance with Sangamo Therapeutics. Though the partnership has produced encouraging early clinical data with a sickle cell therapy highly personalized to the patient, Sanofi now plans to focus on universal approaches to genomic medicines.
Several companies are developing immunotherapies targeting the “don’t eat me” cancer protein CD47. Arch Oncology, which is developing drugs with features that could set them apart from this field, now has $105 million for multiple clinical trials.
Break down the silos. Take control of your provider data.
Takeda Pharmaceutical and Maverick Therapeutics have been R&D partners since 2017. In buying out its partner, Takeda acquires technology and drug candidates that could offer advantages compared to CAR-T therapies, including the potential to treat solid tumors.
Ellume, whose at-home Covid-19 test was cleared by the FDA in December, got a $232 million contract from the Department of Health and Human Services to deliver 8.5 million tests.
Nestle already owns a 25.6% stake in Aimmune worth $473 million, and the deal brings the total value of that investment to $2.6 billion. An analyst wrote that the deal's closing should be "smoother than a fresh jar of Skippy" and was not expected to meet antitrust or competitive hurdles.
Impedimed, which is headquartered in Australia, makes a tool for early detection of lymphedema in cancer patients.
Your varicose or spider veins may indicate an underlying problem, so finding the right vein specialist is crucial. Discover the best vein clinics in Orlando.
Biogen, which Sangamo selected from among several companies in a competitive process, will pay the biotech company $350 million upfront, along with up to $2.37 billion in milestone payments.
Amid a growing number of devices use AI to instruct users but Caption Health says its software is the first that helps clinicians perform echocardiograms.
Palforzia is the first drug to win approval to treat a food allergy. The approval follows a favorable, though not unanimous, vote by an FDA advisory committee in September.
The FDA’s Allergenic Products Advisory Committee voted 7-2 in favor of supporting the efficacy profile of Palforzia, or AR101. Some committee members expressed concerns about a lack of diversity in the Phase III clinical trial.
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
Although the study of AR101 met its primary endpoint, patients on the drug had more allergic reactions than those on placebo. An allergy expert explained that the disparity reflects time needed to build up tolerance to peanut allergen.
An analyst called the beta-thalassemia data - for a cell therapy gene-edited using zinc finger nuclease technology - early but a solid proof of concept for the technology's capability.
The company joins a small but growing list of firms developing drugs targeting CD47, the "don't eat me" immune checkpoint. Another company, further ahead in development, is Forty Seven.
CEO Tony Keating shared some of the lessons learned from the first trial in a Skype interview from Sydney, Australia.
ResApp has developed a smartphone app that uses audio samples of a patient's cough to diagnose acute respiratory diseases. A U.S. pediatric study will assess how the app stacks up against respiratory tests conducted by hospitals to diagnose patients.